In prostate cancer, should BRCA mutation testing be performed using a tissue specimen or a blood specimen?

BRCA Mutation Testing in Prostate Cancer: Blood vs. Tissue Specimen

For metastatic prostate cancer, you need BOTH germline testing (blood specimen) and somatic testing (tissue specimen preferred initially, with ctDNA as alternative), as they serve different but complementary purposes and identify distinct patient populations eligible for PARP inhibitor therapy.

Understanding the Two-Test Requirement

The 2025 ASCO guidelines make clear that BRCA testing in prostate cancer is not a single test but requires two distinct approaches 1:

Germline Testing (Blood Specimen)

• All patients with metastatic prostate cancer should undergo germline genetic testing using blood-derived DNA from peripheral blood leukocytes 1
• This is a strong recommendation with high-quality evidence 1
• Identifies inherited BRCA1/2 mutations present in all cells
• Critical for family counseling and cascade testing of at-risk relatives 1

Somatic Testing (Tissue or ctDNA)

• Patients being considered for biomarker-directed treatment should undergo somatic testing 1
• This is also a strong recommendation with high-quality evidence 1
• Identifies tumor-acquired mutations not present in germline DNA
• For initial somatic testing: archival tissue samples are preferred 1

Specimen Selection Algorithm for Somatic Testing

Initial testing approach 1:

1. First choice: Archival tissue samples (from prostate biopsy or metastatic site)
2. Second choice: ctDNA (blood-based) when:
   • No accessible metastatic site for biopsy
   • Tissue sample failed due to insufficient tumor content (common issue in 18.7% of cases) 2
   • Tissue unavailable or inadequate quality
3. Third choice: Fresh metastatic biopsy when minimal disease burden results in low ctDNA fraction 1

Why Both Tests Matter Clinically

Approximately 25% of metastatic castration-resistant prostate cancer patients have HRR alterations 3, but these can be either germline or somatic:

• Germline-only mutations: Detected only by blood testing, missed by tissue alone
• Somatic-only mutations: Detected only by tumor testing, missed by blood alone
• Both present: Some patients have both germline and acquired somatic alterations

Research from the PROpel trial demonstrates that aggregating both tumor tissue and ctDNA results maximized biomarker identification to 98% of patients while minimizing false negatives 4. When using tissue alone as reference, ctDNA showed 81% positive agreement and 92% negative agreement for BRCA/ATM alterations 5.

Critical Practical Considerations

Tissue Testing Limitations

• Bone metastasis specimens require special attention: Decalcification procedures can compromise DNA integrity and NGS performance 6
• Tumor cellularity requirements: Generally need ≥10-20% neoplastic cells for reliable NGS analysis 6
• Failure rate: Up to 18.7% of prostatic tissue samples cannot be analyzed due to technical issues 2

ctDNA Testing Limitations

• Low ctDNA fraction is the primary limiting factor for detection, particularly with:
  • Minimal disease burden 1
  • Large rearrangements (63% concordance with tissue) 5
  • Homozygous deletions (27% concordance with tissue) 5
• Better concordance for nonsense (93%), splice (87%), and frameshift (86%) alterations 5

Sequential Testing Strategy

Repeat somatic testing should be offered when 1:

• Meaningful change in patient status or treatment plan
• Prior tests were negative or uninformative
• Insufficient or low tumor content in initial sample

Clinical Impact on Treatment Decisions

Patients with pathogenic BRCA1/2 variants (germline OR somatic) are candidates for 1, 4:

• PARP inhibitor monotherapy
• PARP inhibitor with androgen receptor pathway inhibitor combination
• Platinum-based chemotherapy

These patients demonstrate poorer outcomes but respond to targeted therapy, making accurate identification critical for both prognosis and treatment selection 1. The potential incidence of unidentified BRCAm in patients tested with only one method is approximately 1% 4, which represents missed therapeutic opportunities.

Common Pitfalls to Avoid

1. Ordering only germline OR somatic testing: You will miss approximately half of actionable mutations
2. Accepting tissue test failure without pursuing ctDNA: 18.7% tissue failure rate means many patients left untested 2
3. Relying on ctDNA alone in low-volume disease: Low ctDNA fraction reduces sensitivity
4. Testing only at castration-resistance: Consider testing earlier in high-volume metastatic castration-sensitive disease where progression to CRPC is likely 1
5. Using bone biopsy without considering decalcification effects: May compromise molecular testing 6